Medical/Pharmaceuticals
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...
2022-01-14 19:18
3784
Crunchfish Gesture Interaction introduction - Deeply intuitive gestures
STOCKHOLM, Jan. 14, 2022 /PRNewswire/ -- Crunchfish develops AI technology for gesture interaction with exceptional performance, optimized for augmented and virtual reality (AR/VR), automotive and the next generation digital interfaces. An introduction to gesture Interaction was the topic of the ...
2022-01-14 19:17
3371
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines
2022-01-14 08:00
6464
Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed
SHENZHEN, China, Jan. 13, 2022 /PRNewswire/ -- NextSmartShip
2022-01-13 22:40
2541
United Imaging Announces Construction of a World-leading Intelligent R&D and Manufacturing Complex with an Investment of More Than USD 490 million
SHANGHAI, Jan. 13, 2022 /PRNewswire/ -- Recently, the construction of United Imaging's brand new Manufacturing and R&D base of operations officially kicked off. With a total investment ofUSD 490 million and a planned footprint of about 420,000 square meters, the company is creating a modern campu...
2022-01-13 17:43
3021
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...
2022-01-13 17:30
5009
Apex Medical Rebrands to Wellell, redefining core values
NEW TAIPEI CITY, Taiwan, Jan. 13, 2022 /PRNewswire/ -- Apex Medical has placed utmost importance on the value of human life, while providing agile services and high-quality medical devices since 1990. The rebranding in 2022 affirms the determination to establish a global foothold and further evol...
2022-01-13 16:00
3964
LYNC2M Sets to Deliver 41.67 Million Pairs of Nitrile Gloves in February for Its Largest Order in 2022 to Date
LONDON, Jan. 13, 2022 /PRNewswire/ -- Leading Chinese consumer to manufacturer (C2M) medical products supply chain platform, LYNC2M Medical Technology (Beijing ) Co., Ltd. ("LYNC2M"), plans to deliver in February of its first batch of 41.67 million sets of nitrile gloves to UK for a public health ...
2022-01-13 15:34
2491
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
4465
NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldw...
2022-01-13 12:32
4685
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has su...
2022-01-13 10:46
4007
Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference
INCHEON, South Korea, Jan. 12, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference, which is held virtually fromJanuary 10th to 13th with leaders from major pharmaceutical and biopharmaceuti...
2022-01-13 08:52
2937
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
2022-01-13 08:05
7901
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
2022-01-13 04:00
3905
Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
* Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence. TAICHUNG, Taiwan, Jan. 12, 2022 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TWSE:67...
2022-01-13 00:00
3181
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient had been dosed in itsChina phase...
2022-01-12 21:00
2319
Gracell Biotechnologies Unveils Innovation Center in U.S.
SUZHOU, China and PALO ALTO, Calif., Jan. 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
2022-01-12 21:00
2274
Evolved by Nature Announces IDE Approval from the FDA to Initiate a Pivotal Clinical Trial for its first Activated Silk™ Dermal Filler
BOSTON, Jan. 12, 2022 /PRNewswire/ -- Biotechnology company Evolved by Nature announced today that sister company Silk Medical Aesthetics has received Investigational Device Exemption (IDE) approval from the FDA to initiate a pivotal clinical trial for its new dermal filler for the correction of ...
2022-01-12 21:00
3515
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...
2022-01-12 20:43
3312
Bionomics Limited participated in the H.C Wainwright BioConnect Conference
ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually fromJanuary 10-13, 2022. Dr Errol De Souza, Executive C...
2022-01-12 19:00
2874
Week's Top Stories
Most Reposted
DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 277 media titles]
2026-10-06 05:28Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 271 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 269 media titles]
2026-09-30 10:50
Vestas Powers Up Vietnam's Clean Energy Ambitions with Two New Projects Under PDP8 Totaling 16 Wind Turbines
[Picked up by 263 media titles]
2026-10-02 16:27
Sunway University to Host Asia's First Global Tipping Points Conference 2026
[Picked up by 263 media titles]
2026-09-30 12:11
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
23942